195 related articles for article (PubMed ID: 24330315)
1. Pigmentation and melanocyte supply to the epidermis depend on type XVII collagen.
Gostyński A; Pasmooij AM; Del Rio M; Diercks GF; Pas HH; Jonkman MF
Exp Dermatol; 2014 Feb; 23(2):130-2. PubMed ID: 24330315
[TBL] [Abstract][Full Text] [Related]
2. From bedside to bench--reverse translational medicine. Scientific lessons from revertant mosaicism in 'knockout' humans.
Recke A; Ludwig RJ
Exp Dermatol; 2014 Aug; 23(8):549-50. PubMed ID: 24961831
[TBL] [Abstract][Full Text] [Related]
3. Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.
Pasmooij AM; Pas HH; Bolling MC; Jonkman MF
J Clin Invest; 2007 May; 117(5):1240-8. PubMed ID: 17476356
[TBL] [Abstract][Full Text] [Related]
4. Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa.
Umegaki-Arao N; Pasmooij AM; Itoh M; Cerise JE; Guo Z; Levy B; Gostyński A; Rothman LR; Jonkman MF; Christiano AM
Sci Transl Med; 2014 Nov; 6(264):264ra164. PubMed ID: 25429057
[TBL] [Abstract][Full Text] [Related]
5. Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations.
Pasmooij AM; Nijenhuis M; Brander R; Jonkman MF
J Invest Dermatol; 2012 May; 132(5):1374-83. PubMed ID: 22318390
[TBL] [Abstract][Full Text] [Related]
6. Revertant mosaicism due to a second-site mutation in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa.
Pasmooij AM; Garcia M; Escamez MJ; Nijenhuis AM; Azon A; Cuadrado-Corrales N; Jonkman MF; Del Rio M
J Invest Dermatol; 2010 Oct; 130(10):2407-11. PubMed ID: 20574443
[TBL] [Abstract][Full Text] [Related]
7. Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.
Pasmooij AM; Pas HH; Deviaene FC; Nijenhuis M; Jonkman MF
Am J Hum Genet; 2005 Nov; 77(5):727-40. PubMed ID: 16252234
[TBL] [Abstract][Full Text] [Related]
8. A "late-but-fitter revertant cell" explains the high frequency of revertant mosaicism in epidermolysis bullosa.
van den Akker PC; Pasmooij AMG; Joenje H; Hofstra RMW; Te Meerman GJ; Jonkman MF
PLoS One; 2018; 13(2):e0192994. PubMed ID: 29470523
[TBL] [Abstract][Full Text] [Related]
9. Revertant mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation.
Darling TN; Yee C; Bauer JW; Hintner H; Yancey KB
J Clin Invest; 1999 May; 103(10):1371-7. PubMed ID: 10330419
[TBL] [Abstract][Full Text] [Related]
10. Keratinocytes from patients lacking collagen XVII display a migratory phenotype.
Tasanen K; Tunggal L; Chometon G; Bruckner-Tuderman L; Aumailley M
Am J Pathol; 2004 Jun; 164(6):2027-38. PubMed ID: 15161638
[TBL] [Abstract][Full Text] [Related]
11. Successful therapeutic transplantation of revertant skin in epidermolysis bullosa.
Gostyński A; Pasmooij AM; Jonkman MF
J Am Acad Dermatol; 2014 Jan; 70(1):98-101. PubMed ID: 24176523
[TBL] [Abstract][Full Text] [Related]
12. Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy.
Gostynski A; Deviaene FC; Pasmooij AM; Pas HH; Jonkman MF
Br J Dermatol; 2009 Aug; 161(2):444-7. PubMed ID: 19416258
[TBL] [Abstract][Full Text] [Related]
13. Collagen XVII.
Has C; Kern JS
Dermatol Clin; 2010 Jan; 28(1):61-6. PubMed ID: 19945617
[TBL] [Abstract][Full Text] [Related]
14. Ultrastructural findings in epidermolysis bullosa.
Smith LT
Arch Dermatol; 1993 Dec; 129(12):1578-84. PubMed ID: 7504435
[TBL] [Abstract][Full Text] [Related]
15. Life before and beyond blistering: The role of collagen XVII in epidermal physiology.
Natsuga K; Watanabe M; Nishie W; Shimizu H
Exp Dermatol; 2019 Oct; 28(10):1135-1141. PubMed ID: 29604146
[TBL] [Abstract][Full Text] [Related]
16. Natural gene therapy in dystrophic epidermolysis bullosa.
van den Akker PC; Nijenhuis M; Meijer G; Hofstra RM; Jonkman MF; Pasmooij AM
Arch Dermatol; 2012 Feb; 148(2):213-6. PubMed ID: 22004882
[TBL] [Abstract][Full Text] [Related]
17. Generalized atrophic benign epidermolysis bullosa.
Darling TN; Bauer JW; Hintner H; Yancey KB
Adv Dermatol; 1997; 13():87-119; discussion 120. PubMed ID: 9551142
[TBL] [Abstract][Full Text] [Related]
18. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion.
Jonkman MF; Scheffer H; Stulp R; Pas HH; Nijenhuis M; Heeres K; Owaribe K; Pulkkinen L; Uitto J
Cell; 1997 Feb; 88(4):543-51. PubMed ID: 9038345
[TBL] [Abstract][Full Text] [Related]
19. Hemizygosity for a glycine substitution in collagen XVII: unfolding and degradation of the ectodomain.
Tasanen K; Floeth M; Schumann H; Bruckner-Tuderman L
J Invest Dermatol; 2000 Aug; 115(2):207-12. PubMed ID: 10951237
[TBL] [Abstract][Full Text] [Related]
20. Type XVII collagen gene mutations in junctional epidermolysis bullosa and prospects for gene therapy.
Bauer JW; Lanschuetzer C
Clin Exp Dermatol; 2003 Jan; 28(1):53-60. PubMed ID: 12558632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
